期刊
NANO TODAY
卷 36, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2020.101051
关键词
Coronavirus; COVID-19; Influenza, Pulmonary drug delivery; SARS, SARS-CoV-2; MERS, Nanomedicine; Nanotherapeutics; Pathophysiology; Nanotechnology
资金
- Agence Nationale de la Recherche, France under the call Flash COVID-19 [ANR-20-COVI-0093-COVIMUNE]
- European Union Horizon H2020 programme [H2020-SC1-2019-874653INDIGO]
- Department of Biotechnology (DBT), Government of India
- Irish Research Council under the Government of Ireland [GOIPD/2017/1283]
- Science Foundation Ireland (SFI) under the European Regional Development Fund [13/RC/2073]
COVID-19, caused by SARS-CoV-2, has become a global pandemic with significant mortality rates due to pulmonary pathology. Nanomedicine shows promise as a potential strategy in treating COVID-19.
COVID-19, coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic. At the time of writing this (October 14, 2020), more than 38.4 million people have become affected, and 1.0 million people have died across the world. The death rate is un-doubtedly correlated with the cytokine storm and other pathological pulmonary characteristics, as a result of which the lungs cannot provide sufficient oxygen to the body's vital organs. While diversified drugs have been tested as a first line therapy, the complexity of fatal cases has not been reduced so far, and the world is looking for a treatment to combat the virus. However, to date, and despite such promise, we have received very limited information about the potential of nanomedicine to fight against COVID-19 or as an adjunct therapy in the treatment regimen. Over the past two decades, various therapeutic strategies, including direct-acting antiviral drugs, immunomodulators, a few non-specific drugs (simple to complex), have been explored to treat Acute Respiratory Distress Syndrome (ARDS), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), influenza, and sometimes the common flu, thus, correlating and developing specific drugs centric to COVID-19 is possible. This review article focuses on the pulmonary pathology caused by SARS-CoV-2 and other viral pathogens, highlighting possible nanomedicine therapeutic strategies that should be further tested immediately. (C) 2020 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据